目的 探討痰熱清注射液聯(lián)合注射用阿昔洛韋治療老年反復呼吸道感染的臨床療效。方法 選取2016年1月-2017年1月在四川大學華西醫(yī)院進行治療的老年反復呼吸道感染患者105例為研究對象，所有患者均隨機分為對照組（55例）和治療組（50例）。對照組靜脈滴注注射用阿昔洛韋，5 mg/kg，3次/d，隔8 h滴注1次，每次滴注時間在1 h以上。治療組在對照組治療的基礎上靜脈滴注痰熱清注射液，20 mL加入到5%葡萄糖注射液500 mL中，1次/d。兩組患者均持續(xù)治療28 d。觀察兩組的臨床療效，比較兩組的臨床癥狀和免疫功能。結果 治療后，對照組和治療組的總有效率分別為76.36%、98.00%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，治療組癥狀好轉時間、體溫恢復時間、單次感染時間、再次復發(fā)次數(shù)均顯著低于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，治療組免疫球蛋白M（IgM）、免疫球蛋白G（IgG）、免疫球蛋白A（IgA）水平均顯著降低，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；且治療組這些免疫因子水平明顯低于對照組治療同期，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結論 痰熱清注射液聯(lián)合注射用阿昔洛韋治療老年反復呼吸道感染具有較好的臨床療效，可改善患者臨床癥狀，提高免疫水平，復發(fā)率低，具有一定的臨床推廣應用價值。

Objective To investigate the clinical effect of Tanreqing Injection combined with Aciclovir for injection in treatment of recurrent respiratory tract infections in the elderly. Methods Elderly patients (105 cases) with respiratory tract infections in West China Hospital of Sichuan University from January 2016 to January 2017 were randomly divided into the control group (55 cases) and the treatment group (50 cases). Patients in the control group were iv administered with Aciclovir for injection, 5 mg/kg, three times daily, each time interval was 8 h, and the time of infusion was above 1 h. Patients in the treatment group were iv administered with Tanreqing Injection on the basis of the control group, 20 mL added into 5% glucose solution 500 mL, once daily. Patients in two groups were treated for 28 d. After treatment, the clinical efficacies were evaluated, and clinical symptoms and immune function in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 76.36% and 98.00%, respectively, and there was difference between two groups (P<0.05). After treatment, symptoms improvement time, body temperature recovery time, single infection time, and relapse frequency in the treatment group were significantly lower than those in the control groups, and there was difference between two groups (P<0.05). After treatment, the levels of immunoglobulin M (IgM), IgG, and IgA in the treatment group were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the immune factors levels in the treatment group were significantly lower than those in the control group in the same period, with significant difference between two groups (P<0.05). Conclusion Tanreqing Injection combined with Aciclovir for injection has clinical curative effect in treatment of recurrent respiratory tract infections in the elderly, can improve the clinical symptoms of patients, and increase the immune levels of patients, with the low recurrence rate, which has a certain clinical application value.